NVO

bearish · high conviction track record →

Novo Nordisk Faces Sell-Off on Weak Outlook

Watch: Q1 2026 earnings in late April will reveal whether sales guidance is revised down further, confirming the pace of Lilly's market share gains.

Full analysis

Novo Nordisk shares plunged 41.11% in the past year, closing at $37.98 on April 13. Vltava Fund sold its position in Q1 2026, citing a deteriorating financial outlook and unpredictable future. Despite 55 hedge funds holding shares at end-2025, institutional sentiment appears cautious amid ongoing margin compression and share loss to Lilly.

The sell-off reflects fundamental concerns over Novo Nordisk's profitability and market share erosion, potentially prolonging the stock's downtrend and undermining recovery prospects.

Compare

Evidence

12 signals · latest 1d ago

Get alerted when NVO changes direction

We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.